Aerovate Therapeutics (AVTE) Competitors $9.04 -0.10 (-1.09%) As of 10/7/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsDividendEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AVTE vs. SPRY, PGEN, PHAR, TNGX, URGN, NBTX, CRMD, RLAY, MNMD, and TSHAShould you be buying Aerovate Therapeutics stock or one of its competitors? The main competitors of Aerovate Therapeutics include ARS Pharmaceuticals (SPRY), Precigen (PGEN), Pharming Group (PHAR), Tango Therapeutics (TNGX), Urogen Pharma (URGN), Nanobiotix (NBTX), CorMedix (CRMD), Relay Therapeutics (RLAY), Mind Medicine (MindMed) (MNMD), and Taysha Gene Therapies (TSHA). These companies are all part of the "pharmaceutical products" industry. Aerovate Therapeutics vs. Its Competitors ARS Pharmaceuticals Precigen Pharming Group Tango Therapeutics Urogen Pharma Nanobiotix CorMedix Relay Therapeutics Mind Medicine (MindMed) Taysha Gene Therapies ARS Pharmaceuticals (NASDAQ:SPRY) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, risk, earnings, valuation, institutional ownership and dividends. Which has stronger valuation & earnings, SPRY or AVTE? ARS Pharmaceuticals has higher revenue and earnings than Aerovate Therapeutics. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Aerovate Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioARS Pharmaceuticals$112.34M10.20$8M-$0.49-23.66Aerovate TherapeuticsN/AN/A-$75.52M-$1.70-5.32 Is SPRY or AVTE more profitable? Aerovate Therapeutics has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -42.74%. ARS Pharmaceuticals' return on equity of -21.85% beat Aerovate Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets ARS Pharmaceuticals-42.74% -21.85% -15.88% Aerovate Therapeutics N/A -90.19%-77.47% Does the media prefer SPRY or AVTE? In the previous week, ARS Pharmaceuticals had 7 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 7 mentions for ARS Pharmaceuticals and 0 mentions for Aerovate Therapeutics. ARS Pharmaceuticals' average media sentiment score of 0.01 beat Aerovate Therapeutics' score of 0.00 indicating that ARS Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment ARS Pharmaceuticals Neutral Aerovate Therapeutics Neutral Which has more risk & volatility, SPRY or AVTE? ARS Pharmaceuticals has a beta of 0.84, suggesting that its stock price is 16% less volatile than the S&P 500. Comparatively, Aerovate Therapeutics has a beta of 0.95, suggesting that its stock price is 5% less volatile than the S&P 500. Do analysts rate SPRY or AVTE? ARS Pharmaceuticals currently has a consensus price target of $33.80, indicating a potential upside of 191.61%. Given ARS Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe ARS Pharmaceuticals is more favorable than Aerovate Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ARS Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals & insiders believe in SPRY or AVTE? 68.2% of ARS Pharmaceuticals shares are held by institutional investors. 33.5% of ARS Pharmaceuticals shares are held by insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. SummaryARS Pharmaceuticals beats Aerovate Therapeutics on 13 of the 16 factors compared between the two stocks. Get Aerovate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AVTE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AVTE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVTE vs. The Competition Export to ExcelMetricAerovate TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$262.02M$1.01B$9.05B$10.58BDividend YieldN/A4.84%5.69%4.71%P/E Ratio-3.021.2485.8427.32Price / SalesN/A142.47535.95201.92Price / CashN/A17.6437.9261.55Price / Book2.287.3613.026.76Net Income-$75.52M-$7.88M$3.30B$275.79M7 Day Performance-0.77%27.36%4.69%2.44%1 Month Performance20.86%29.11%9.86%8.86%1 Year Performance-87.34%-7.89%84.90%35.45% Aerovate Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVTEAerovate TherapeuticsN/A$9.04-1.1%N/A-87.4%$262.02MN/A-3.0220High Trading VolumeSPRYARS Pharmaceuticals2.9047 of 5 stars$10.03+3.2%$33.17+230.6%-20.0%$991.52M$112.34M-20.4890Analyst ForecastPGENPrecigen4.4233 of 5 stars$3.30-9.2%$8.25+150.4%+276.3%$981.82M$4.34M-7.85190Analyst ForecastGap UpPHARPharming Group2.3161 of 5 stars$14.25+0.5%$30.00+110.5%+69.5%$976.27M$339.84M-109.61280Positive NewsAnalyst ForecastShort Interest ↑Gap UpTNGXTango Therapeutics1.9828 of 5 stars$8.37-0.9%$10.50+25.5%+0.3%$930.69M$24.30M-6.2990Analyst ForecastURGNUrogen Pharma3.9111 of 5 stars$19.99+4.5%$32.00+60.1%+32.2%$924.88M$90.40M-6.02200Analyst ForecastNBTXNanobiotix1.2723 of 5 stars$19.01+5.5%$11.00-42.1%+423.2%$911.10M$39.18M0.00100Analyst ForecastAnalyst RevisionGap DownHigh Trading VolumeCRMDCorMedix2.9198 of 5 stars$11.64-1.8%$18.00+54.7%+16.5%$908.22M$121.48M15.5130Analyst DowngradeGap UpRLAYRelay Therapeutics2.8269 of 5 stars$5.24+1.0%$16.50+214.8%-2.2%$903.77M$10.01M-2.69330Positive NewsMNMDMind Medicine (MindMed)2.2731 of 5 stars$11.82-1.9%$26.50+124.3%+142.6%$899.08MN/A-7.7240Analyst ForecastTSHATaysha Gene Therapies2.5249 of 5 stars$3.28+3.6%$8.29+153.0%+151.7%$893.42M$8.33M-9.63180Positive NewsAnalyst Forecast Related Companies and Tools Related Companies ARS Pharmaceuticals Competitors Precigen Competitors Pharming Group Competitors Tango Therapeutics Competitors Urogen Pharma Competitors Nanobiotix Competitors CorMedix Competitors Relay Therapeutics Competitors Mind Medicine (MindMed) Competitors Taysha Gene Therapies Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AVTE) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aerovate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aerovate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
